Mindbio Therapeutics Corp. (TSE:MBIO) has released an update.
Mindbio Therapeutics Corp. has developed a shelf-stable microdosing formulation of LSD, MB22001, showing promise in treating depression with a 12-month room temperature shelf life. The formulation is advancing through multiple Phase 2B clinical trials, demonstrating significant reductions in depressive symptoms and anxiety.
For further insights into TSE:MBIO stock, check out TipRanks’ Stock Analysis page.
